Mesenchymal Stem Cell
Pre-clinicalCompleted 0 watching 0 views this week💤 Quiet
23
Development Stage
1
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Decompensated Liver Cirrhosis
Conditions
Decompensated Liver Cirrhosis
Trial Timeline
Mar 7, 2018 → Oct 12, 2023
NCT ID
NCT03472742About Mesenchymal Stem Cell
Mesenchymal Stem Cell is a pre-clinical stage product being developed by Rohto Pharmaceutical for Decompensated Liver Cirrhosis. The current trial status is completed. This product is registered under clinical trial identifier NCT03472742. Target conditions include Decompensated Liver Cirrhosis.
Hype Score Breakdown
Clinical
5
Activity
2
Company
10
Novelty
2
Community
1
Clinical Trials (3)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04522986 | Phase 1 | Completed |
| NCT03472742 | Pre-clinical | Completed |
| NCT03254758 | Phase 1/2 | Completed |
Competing Products
5 competing products in Decompensated Liver Cirrhosis
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| TRV027 Dose #1 + TRV027 Dose #2 + TRV027 Dose #3 + Placebo | Trevena | Phase 2 | 44 |
| Mesenchymal stem cell | Rohto Pharmaceutical | Phase 1/2 | 41 |
| Aliskiren + Placebo | Novartis | Phase 3 | 77 |
| BMS-986259 | Bristol Myers Squibb | Phase 2 | 51 |
| Albutein 20% | Grifols | Phase 3 | 74 |